Alnylam Pharmaceuticals
ALNY
#645
Rank
HK$241.56 B
Marketcap
HK$1,873
Share price
-6.73%
Change (1 day)
41.15%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : HK$10.13 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is HK$10.13 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31HK$10.19 B-1.17%
2022-12-31HK$10.31 B32.61%
2021-12-31HK$7.77 B92.53%
2020-12-31HK$4.04 B70.75%
2019-12-31HK$2.36 B907.21%
2018-12-31HK$0.23 B0.23%
2017-12-31HK$0.23 B-79.85%
2016-12-31HK$1.16 B
2007-12-31HK$52.69 M-25.84%
2006-12-31HK$71.05 M23.93%
2005-12-31HK$57.33 M2.46%
2004-12-31HK$55.96 M288.36%
2003-12-31HK$14.4 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
HK$0.91 B-90.93%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$21.05 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$10.88 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$2.09 B-79.30%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$5.25 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$250.37 B 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$198.22 B 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
HK$150.06 B 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel